Protalix BioTherapeutics, Inc. (PLX) Operating cash flow 2016–2025
Protalix BioTherapeutics, Inc. (PLX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.0MFY2025 · since FY2016: -$32.1M → -$12.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.0M | -238.3% |
| FY2024 | $8.7M | +758.1% |
| FY2023 | -$1.3M | +94.7% |
| FY2022 | -$25.0M | -143.1% |
| FY2021 | -$10.3M | +60.6% |
| FY2020 | -$26.1M | -34.9% |
| FY2019 | -$19.4M | -150.0% |
| FY2018 | -$7.7M | +22.5% |
| FY2017 | -$10.0M | +68.9% |
| FY2016 | -$32.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice